Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy
We also provide end-to-end assistance and guide you through the entire process of getting the medicine to you, with thousands of orders shipped to clients in over 30 countries, we have been associated with clinicians for the treatment of hepatitis, oncology, and nephrology, and critical care patients worldwide
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist phase 2 trial in type 2 diabetes
The conflicting data in some clinical studies may be explained by various factors: [1] most cohort studies lacked individual validation of fractures as primary outcomes, [2] the studies had short follow-up duration and [3] did not consider important risk factors for osteoporosis such as BMD (even though BMD is not a good method for diagnosing osteoporosis in T2DM), and [4] some studies included medications that affect fracture risk, such as corticosteroids or antidepressants
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update